Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Sep 27, 2023

Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences

Sep 11, 2023

Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September

Sep 7, 2023

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

Aug 28, 2023

Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update

Aug 11, 2023

Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August

Aug 8, 2023

Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Jul 26, 2023

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2023

Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference

Jun 27, 2023

Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference

Jun 21, 2023